TWST
Twist Bioscience Corporation · Healthcare · Medical - Diagnostics & Research
动量输入（同类管理人）： 持有人广度 0.0% · 股份流向 -2.6% · 净新建仓位 -5.6% · 公式
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 4.77K | $725,583 | n/a | −2 |
| Q2 2026 | 113 | +8 | 54.74M | $5.63B | +14 | −6 |
| Q1 2026 | 108 | +15 | 51.20M | $2.43B | +20 | −5 |
| Q4 2025 | 92 | -2 | 51.46M | $1.63B | +1 | −3 |
| Q3 2025 | 18 | 0 | 32.97M | $927.70M | +1 | −2 |
| Q2 2025 | 16 | -3 | 28.73M | $1.06B | n/a | −3 |
| Q1 2025 | 16 | +1 | 15.75M | $618.44M | +2 | −1 |
| Q4 2024 | 15 | 0 | 15.20M | $706.21M | n/a | n/a |
| Q3 2024 | 14 | +1 | 11.38M | $514.14M | +2 | −1 |
| Q2 2024 | 13 | n/a | 12.61M | $621.59M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 6.73M | +5.1% | $189.29M | 1.1% | ▲ Add | 6 | SEC ↗ |
| 2 | BlackRock ✦ (被动) | 6.18M | -1.6% | $173.86M | 0.0% | ▼ Trim | 2 | SEC ↗ ×15 |
| 3 | The Vanguard Group ✦ (被动) | 5.77M | -1.1% | $162.32M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 4 | State Street Global Advisors ✦ (被动) | 3.09M | +23.5% | $86.93M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | JPMorgan Chase ✦ | 2.04M | n/a | $57.31M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 6 | Millennium Management ✦ | 1.79M | +151.6% | $50.48M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 1.63M | n/a | $45.78M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 8 | Morgan Stanley ✦ | 1.49M | n/a | $41.99M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 9 | Geode Capital Management ✦ (被动) | 1.45M | +1.7% | $40.76M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Baillie Gifford ✦ | 1.26M | +62.8% | $35.53M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 11 | Point72 Asset Management ✦ | 530.03K | -75.4% | $14.92M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Wellington Management ✦ | 299.81K | -48.0% | $8.44M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 13 | Fidelity (FMR) ✦ | 219.53K | +1.1% | $6.18M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 14 | AQR Capital Management ✦ | 207.91K | +40.0% | $5.85M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 15 | Citadel Advisors ✦ | 115.25K | -92.3% | $3.24M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 73.75K | -36.4% | $2.08M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 53.85K | +9.3% | $1.52M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | Marshall Wace ✦ | 44.07K | 新增 | $1.24M | 0.0% | New | 1 | SEC ↗ ×2 |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $1.24M | 0.0% |
已清仓
| Norges Bank | $737,382 | 曾为 0.0% |
| Renaissance Technologies | $507,702 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 279 持有人, 76.80M 股份, $3.56B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Officer · 2.46K 股 · $384,823
Officer, Director · 45 股 · $9,336
Officer, Director · 146 股 · $30,199
Officer, Director · 297 股 · $61,116
Officer, Director · 290 股 · $59,392
Officer, Director · 432 股 · $87,958
Officer, Director · 1.02K 股 · $205,763
Officer, Director · 1.84K 股 · $368,806
Officer, Director · 481 股 · $96,804
Officer · 25.71K 股 · $4.86M
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论